- Home
- LFT vs ASMB Comparison
LFT vs ASMB Comparison
Compare LFT & ASMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LFT
- ASMB
- Stock Information
- Founded
- LFT 2012
- ASMB 2005
- Country
- LFT United States
- ASMB United States
- Employees
- LFT N/A
- ASMB N/A
- Industry
- LFT Real Estate Investment Trusts
- ASMB Biotechnology: Pharmaceutical Preparations
- Sector
- LFT Real Estate
- ASMB Health Care
- Exchange
- LFT Nasdaq
- ASMB Nasdaq
- Market Cap
- LFT 125.6M
- ASMB 130.2M
- IPO Year
- LFT N/A
- ASMB 2010
- Fundamental
- Price
- LFT $2.45
- ASMB $17.39
- Analyst Decision
- LFT Hold
- ASMB Strong Buy
- Analyst Count
- LFT 2
- ASMB 3
- Target Price
- LFT N/A
- ASMB $33.00
- AVG Volume (30 Days)
- LFT 109.3K
- ASMB 22.2K
- Earning Date
- LFT 08-11-2025
- ASMB 08-07-2025
- Dividend Yield
- LFT 16.40%
- ASMB N/A
- EPS Growth
- LFT N/A
- ASMB N/A
- EPS
- LFT 0.20
- ASMB N/A
- Revenue
- LFT $27,066,283.00
- ASMB $32,154,000.00
- Revenue This Year
- LFT $152.58
- ASMB $0.04
- Revenue Next Year
- LFT N/A
- ASMB N/A
- P/E Ratio
- LFT $12.36
- ASMB N/A
- Revenue Growth
- LFT N/A
- ASMB 148.33
- 52 Week Low
- LFT $2.22
- ASMB $7.75
- 52 Week High
- LFT $2.84
- ASMB $19.93
- Technical
- Relative Strength Index (RSI)
- LFT 40.78
- ASMB 71.41
- Support Level
- LFT $2.45
- ASMB $15.84
- Resistance Level
- LFT $2.63
- ASMB $17.60
- Average True Range (ATR)
- LFT 0.07
- ASMB 0.93
- MACD
- LFT -0.01
- ASMB 0.01
- Stochastic Oscillator
- LFT 2.44
- ASMB 88.04
About LFT Lument Finance Trust Inc.
Lument Finance Trust Inc operates as a real estate investment trust. The company is engaged in investment, financing, and management of a portfolio of commercial real estate debt investments. It invests in transitional floating-rate commercial real estate mortgage loans, mezzanine loans, preferred equity, commercial mortgage-backed securities, fixed-rate loans, construction loans, and other CRE debt instruments.
About ASMB Assembly Biosciences Inc.
Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.